Mepolizumab Beneficial in COPD With Eosinophilic Phenotype
Lower annual rate of moderate, severe exacerbations for patients receiving 100 mg mepolizumab
A biologic that targets interleukin-5 could reduce COPD exacerbations in patients with high blood eosinophil counts, new research shows.Medscape Medical News
(MedPage Today) -- May work better for patients with higher blood eosinophil counts
Little attention has been given to the impact of chronic obstructive pulmonary disease (COPD) on work productivity loss. Individuals with COPD are at risk of reduced working hours, absenteeism, presenteeism and early retirement . Studies have been focused mostly on patients attending outpatient clinics , which exclude individuals with undiagnosed COPD, thus limiting the external validity of the findings. There are very few population-based cohort studies [3–6], few reports on presenteeism , and a lack of objective measures to define COPD . There would be value in knowing the extent of work productivity lo...
Active smoking in stable COPD subjects significantly increased eosinophil accumulation in the distal airspaces, but not in sputum or peripheral blood. Our findings support the need to investigate this cell-type as a potential driver of COPD symptomatology and progression.
Individuals with asthma and chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) have a more rapid decline in lung function, more frequent exacerbations and worse quality of life than those with asthma or COPD alone [1–3]. Various risk factors may be associated with the development of ACOS, such as smoking history and status, obesity, comorbidity and indoor and outdoor environmental exposures [1, 4–6]. The risk of developing ACOS may vary substantially by region, since demographic and environmental risk factors and community characteristics are not geographically homogeneous. Here, we use popula...
iPSC-MSCs protect against oxidative stress-induced mitochondrial dysfunction, apoptosis, hyper-responsiveness and inflammation in the airways. These findings highlight the potential use of iPSC-MScs as a novel cell-based therapy for COPD.
Conclusions: These findings suggest that the potential magnitude of health benefits of air quality policies targeting O3, health co-benefits of climate mitigation policies, and health implications of climate change-driven changes in O3 concentrations, are larger than previously thought. https://doi.org/10.1289/EHP1390 Received: 17 November 2016 Revised: 19 June 2017 Accepted: 20 June 2017 Published: 28 August 2017 Address correspondence to C.S. Malley, Stockholm Environment Institute, Environment Dept., Environment Building, Wentworth Way, University of York, York, YO10 5NG, UK. Telephone: 44 1904 323685. Email: chri...
PMID: 28836543 [PubMed - in process]
(MedPage Today) -- Asthma is most common respiratory disease, COPD is most deadly